JP2019523653A5 - - Google Patents

Download PDF

Info

Publication number
JP2019523653A5
JP2019523653A5 JP2019514173A JP2019514173A JP2019523653A5 JP 2019523653 A5 JP2019523653 A5 JP 2019523653A5 JP 2019514173 A JP2019514173 A JP 2019514173A JP 2019514173 A JP2019514173 A JP 2019514173A JP 2019523653 A5 JP2019523653 A5 JP 2019523653A5
Authority
JP
Japan
Prior art keywords
seq
antibody
heavy chain
item
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019514173A
Other languages
English (en)
Japanese (ja)
Other versions
JP7210026B2 (ja
JP2019523653A (ja
Filing date
Publication date
Priority claimed from PCT/CN2016/083653 external-priority patent/WO2017201731A1/en
Application filed filed Critical
Publication of JP2019523653A publication Critical patent/JP2019523653A/ja
Publication of JP2019523653A5 publication Critical patent/JP2019523653A5/ja
Application granted granted Critical
Publication of JP7210026B2 publication Critical patent/JP7210026B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019514173A 2016-05-27 2017-05-27 抗体、抗体を含む組成物およびキット、ならびにそれらの使用方法 Active JP7210026B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/083653 2016-05-27
PCT/CN2016/083653 WO2017201731A1 (en) 2016-05-27 2016-05-27 Antibodies, composition and kits comprising same, and methods of use thereof
PCT/CN2017/086280 WO2017202387A1 (en) 2016-05-27 2017-05-27 Antibodies, composition and kits comprising same, and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2019523653A JP2019523653A (ja) 2019-08-29
JP2019523653A5 true JP2019523653A5 (https=) 2020-07-09
JP7210026B2 JP7210026B2 (ja) 2023-01-23

Family

ID=60410923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019514173A Active JP7210026B2 (ja) 2016-05-27 2017-05-27 抗体、抗体を含む組成物およびキット、ならびにそれらの使用方法

Country Status (8)

Country Link
US (2) US11192946B2 (https=)
EP (1) EP3464346A4 (https=)
JP (1) JP7210026B2 (https=)
KR (1) KR102540512B1 (https=)
CN (1) CN109563155B (https=)
AU (1) AU2017269526B2 (https=)
CA (1) CA3025217A1 (https=)
WO (2) WO2017201731A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017201731A1 (en) 2016-05-27 2017-11-30 Beijing Vdjbio Co., Ltd. Antibodies, composition and kits comprising same, and methods of use thereof
RU2020121415A (ru) * 2017-11-30 2021-12-30 Био-Тера Солюшнз, Лтд. Жидкий препарат гуманизированного антитела для лечения заболеваний, опосредованных ил-6
CN119662544A (zh) 2018-03-14 2025-03-21 湖南思为康医药有限公司 用于降低毒性的免疫细胞修饰以及其在过继细胞疗法中的用途
WO2019241216A1 (en) * 2018-06-14 2019-12-19 Bioatla, Llc Multi-specific antibody constructs
CN113677356A (zh) * 2019-01-07 2021-11-19 湖南思为康医药有限公司 用于降低毒性的共表达嵌合抗原受体和il-6拮抗剂的修饰免疫细胞及其在过继细胞疗法中的用途
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
CN113316587B (zh) * 2019-05-20 2024-03-26 南通壹宸生物医药科技有限公司 一种双特异性分子及其制备与用途
WO2021164107A1 (zh) * 2020-02-19 2021-08-26 中国科学技术大学 Il-6受体抗体的新用途
CN116261448A (zh) * 2020-08-19 2023-06-13 百奥泰生物制药股份有限公司 用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂
CN118632873A (zh) * 2022-11-07 2024-09-10 北京伟德杰生物科技有限公司 双特异性抗体及其应用
CN118591566A (zh) * 2022-11-07 2024-09-03 北京伟德杰生物科技有限公司 双功能融合蛋白及其应用
CN120818056A (zh) * 2024-04-15 2025-10-21 北京伟德杰生物科技有限公司 抗白介素6受体的抗体及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1490494A1 (en) 2002-04-01 2004-12-29 Walter Reed Army Institute of Research Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
WO2005090405A1 (ja) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン-6受容体に対するヒト型化抗体のサブタイプ
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトil−6受容体に対する高親和性抗体
WO2008000632A1 (en) 2006-06-29 2008-01-03 Dsm Ip Assets B.V. A method for achieving improved polypeptide expression
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
MX2010003329A (es) * 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de il-6.
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
MX342810B (es) * 2011-03-03 2016-10-13 Apexigen Inc Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
US9487590B2 (en) * 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
WO2017201731A1 (en) 2016-05-27 2017-11-30 Beijing Vdjbio Co., Ltd. Antibodies, composition and kits comprising same, and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2019523653A5 (https=)
RU2464276C2 (ru) Улучшенные нанотела против фактора некроза опухоли-альфа
AU2009347206B2 (en) Isolation and purification of antibodies using Protein A affinity chromatography
WO2022031871A4 (en) Compositions and methods related to il27 receptor binding
CN107001458B (zh) 基于可变结构域vl和vhh衍生物的高亲和力和聚集稳定的抗体
JP2021063129A5 (https=)
JP2017018106A5 (https=)
JP2023504914A5 (https=)
US20200291063A1 (en) Method for separation of monomeric polypeptides from aggregated polypeptides
JP2015528003A5 (https=)
RU2018111508A (ru) Анти-LAG-3 антитела
JP7384498B2 (ja) 抗ヒトインターロイキン23モノクローナル抗体及びその使用
CN118324847A (zh) 单域抗原结合性分子的纯化方法
JP2012516158A5 (https=)
JP2021511830A5 (https=)
SI2481753T1 (en) Anti-IL-17 Antibodies
CN102770537A (zh) 用于纯化多肽多聚体的多肽的修饰方法
RU2012111597A (ru) Новые il-17-связывющие соединения и их медицинское применение
AU2017361846A1 (en) T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
CN117500824A (zh) 包含IL-10或TGF-β激动剂多肽的嵌合分子
JP2023553694A5 (https=)
TW201024319A (en) Antibodies that bind to IL-12 and methods of purifying the same
JP7680078B2 (ja) 抗ヒトインターフェロンα受容体1モノクローナル抗体及びその使用
JP2023510871A5 (https=)
JP2023522030A5 (https=)